[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Citius Pharmaceuticals Inc (CTXR)

Citius Pharmaceuticals Inc (CTXR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,574
  • Shares Outstanding, K 22,376
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,430 K
  • EBIT $ -37 M
  • EBITDA $ -37 M
  • 60-Month Beta 1.38
  • Price/Sales 2.57
  • Price/Cash Flow N/A
  • Price/Book 0.13
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.45
  • Most Recent Earnings $-0.38 on 02/13/26
  • Next Earnings Date 05/13/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 253.71% (-4.15%)
  • Historical Volatility 130.13%
  • IV Percentile 45%
  • IV Rank 22.35%
  • IV High 930.28% on 12/09/25
  • IV Low 58.96% on 01/20/26
  • Expected Move (DTE 14) 0.1785 (25.50%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 24
  • Volume Avg (30-Day) 89
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 5,655
  • Open Int (30-Day) 5,204
  • Expected Range 0.5215 to 0.8785

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-1.50
  • Growth Rate Est. (year over year) +66,700.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5700 +22.81%
on 04/29/26
1.0300 -32.04%
on 04/23/26
-0.1431 (-16.97%)
since 04/01/26
3-Month
0.5700 +22.81%
on 04/29/26
1.0750 -34.88%
on 03/11/26
-0.0401 (-5.42%)
since 01/30/26
52-Week
0.5700 +22.81%
on 04/29/26
2.4800 -71.77%
on 07/03/25
-0.0220 (-3.05%)
since 05/01/25

Most Recent Stories

More News
Citius Oncology Ships First International Order of LYMPHIRâ„¢ to Europe

Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch

CTXR : 0.7000 (+0.57%)
CTOR : 0.9449 (+7.39%)
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

CRANFORD, N.J. , April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization...

CTXR : 0.7000 (+0.57%)
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

CRANFORD, N.J. , April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization...

CTXR : 0.7000 (+0.57%)
Citius Oncology Provides Commercial Update on LYMPHIRâ„¢ Launch Highlighting Early Adoption and Expanding Clinical Development

Broad institutional uptake among leading cancer centers and payer coverage supports early prescribing momentum and clinical integration

CTXR : 0.7000 (+0.57%)
CTOR : 0.9449 (+7.39%)
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIRâ„¢ in Discussions with Leading Cutaneous Lymphoma Experts

Citius Oncology to meet with cutaneous T-cell lymphoma (CTCL) specialists as part of ongoing clinical engagement; one-on-one meetings available

CTXR : 0.7000 (+0.57%)
CTOR : 0.9449 (+7.39%)
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy

CTXR : 0.7000 (+0.57%)
CTOR : 0.9449 (+7.39%)
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program

Non-dilutive capital supports continued execution and value creation

CTXR : 0.7000 (+0.57%)
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIRâ„¢

Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results

CTXR : 0.7000 (+0.57%)
CTOR : 0.9449 (+7.39%)
Citius Oncology Expands International Distribution of LYMPHIRâ„¢ to European Union Through Exclusive Agreement with Uniphar

Third international distribution agreement further advances global access strategy with major markets in Europe

CTXR : 0.7000 (+0.57%)
CTOR : 0.9449 (+7.39%)
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Cancer Immunotherapy, LYMPHIRâ„¢, launched in the U.S. in December 2025

CTXR : 0.7000 (+0.57%)
CTOR : 0.9449 (+7.39%)

Business Summary

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 0.8028
2nd Resistance Point 0.7612
1st Resistance Point 0.7306
Last Price 0.7000
1st Support Level 0.6584
2nd Support Level 0.6168
3rd Support Level 0.5862

See More

52-Week High 2.4800
Fibonacci 61.8% 1.7504
Fibonacci 50% 1.5250
Fibonacci 38.2% 1.2996
Last Price 0.7000
52-Week Low 0.5700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.